结节性痒疹病因及诊疗现状
摘要
对患者生活质量造成严重影响。病变通常持续数月甚至数年。瘙痒性病变在临床上非常典型，由表皮棘皮病、真皮
纤维化和致密炎症浸润组成。神经元对瘙痒敏感化和瘙痒-抓挠循环的发展是其发病机制[1]。治疗的传统方法包括局
部和系统性使用皮质类固醇、抗组胺药、光疗等，但其疗效非常有限。近年来，生物制剂在免疫相关皮肤病中的应
用逐渐增多，逐渐成为PN治疗新希望。
关键词
全文:
PDF参考
[1]Ständer S.How to define chronic pruritus: symptom
or disease? ExpDermatol.2019;28:1461–1465.doi:10.1111/
exd.13953.
[2]Carrascosa JM,Munera M.Prurigo nodularis:the
difference between knowing the path and walking the path.Br
J Dermatol.2024 Jul 3:ljae259.doi:10.1093/bjd/ljae259.Epub
ahead of print.PMID:38959437.
[3]Zeidler C,Pereira MP,Dugas M,et al.The burden in
chronic prurigo: patients with chronic prurigo suffer more
than patients with chronic pruritus on non-lesional skin: a
comparative,retrospective,explorative statistical analysis of
4484 patients in a real- world cohort.J Eur Acad Dermatol
Venereol.2021;35:738–43.
[4]Pereira MP,Hoffmann V,Weisshaar E,et al.Chronic
nodular prurigo:clinical profile and burden.A European cross-sectional study.J Eur Acad Dermatol Venereol.2020;34:2373–
83.10.1111/jdv.16309.
[5]Schielein L,Ziehfreund S,Biedermann T,et al.”When
you do not feel comfortable in your skin, you cannot get out
of it”-A Qualitative Interview Study exploring Psychosocial
Impact and Coping Strategies among Patients with Prurigo
Nodularis.Br J Dermatol.2024 Jun 28:ljae 274.doi:10.1093/
bjd/ljae274.Epub ahead of print.PMID:38938179.
[6]Pereira MP,Zeidler C,Wallengren J,et al.Chronic
nodular prurigo: a European cross-sectional study of patient
perspectives on therapeutic goals and satisfaction.Acta Derm V
enereol.2021;101:adv00403.10.2340/00015555-3726.
[7]Jørgensen KM,Egeberg A,Gislason GH,et
al.Anxiety,depression and suicide in patients with prurigo
nodularis.J Eur Acad Dermatol Venereol.2017;31:e106–e107.
doi:10.1111/jdv.13827.
[8]Schneider G,Zeidler C,Pereira MP,et al.One third
of chronic prurigo patients scratch automatically and in the
absence of itch-a naturalistic study of 1142 patients.J Eur
Acad Dermatol Venereol.2022;36:e297–e300.doi:10.1111/
jdv.17777.
[9]Stumpf A,Ständer S,Warlich B,et al.Relations
between the characteristics and psychological comorbidities of
chronic pruritus differ between men and women: women are
more anxious than men.Br J Dermatol.2015;172:1323–1328.
doi:10.1111/bjd.13492.
[10]Boozalis E,Tang O,Patel S,et al.Ethnic differences
and comorbidities of 909 prurigo nodularis patients.J Am
Acad Dermatol.2018;79:714–9 (e3)
[11]Kawai R,Ichimasu N,Katagiri K.IL-4 and IL-13
are not involved in IL-31-induced itch-associated scratching
behaviour in mice.Exp Dermatol.2024 Jun;33(6):e15115.
doi:10.1111/exd.15115.PMID:38855893.
[12]Hashimoto T,Nattkemper L.A,Kim H.S,et al.Dermal
Periostin: A New Player in Itch of Prurigo Nodularis.Acta
Derm.Venereol.2021;101:adv00375.doi:10.2340/00015555-
3702.
[13]Zhong W,Wu X,Zhang W,et al.Aberrant
Expression of Histamine-independent Pruritogenic Mediators
in Keratinocytes may be Involved in the Pathogenesis of
Prurigo Nodularis.Acta Derm.Venereol.2019;99:579–586.
doi:10.2340/00015555-3150.
[14]Hashimoto T,Nattkemper L.A,Kim H.S,et al.Itch
Intensity in Prurigo Nodularis is Closely Related to Dermal
Interleukin-31,Oncostatin M,IL-31 Recept or Alpha and
Oncostatin M Receptor Beta.Exp.Dermatol.2021doi:10.1111/
exd.14279.
[15]Witte F,Ständer S,Zeidler C.Therapie der
chronischen Prurigo:Update und Perspektive[Treatment
o f chronic prurigo:update and perspectives].
Dermatologie(Heidelb).2024 Jun 13.German.doi:10.1007/
s00105-024-05375-y.Epub ahead of print.PMID:38869847.
[ 1 6 ] Z e i d l e r C , P e r e i r a M P , A u g u s t i n M , e t
al.Investigator’s global assessment of chronic prurigo:a new
instrument for use in clinical trials. Acta Derm Venereol.2021;
101:adv00401.10.2340/00015555-3701.
[17]Ständer S,Pereira MP,Berger T,et al.IFSI-guideline on chronic prurigo including prurigo
nodularis. Itch.2020;5:e42–e42.doi:10.1097/
itx.0000000000000042.
[18]Storck M,Sandmann S,Bruland P,et al.Pruritus
Intensity Scales across Europe: a prospective validation
study.J Eur Acad Dermatol Venereol.2021;35:1176–1185.
doi:10.1111/jdv.17111.
[19]Reich A,Chatzigeorkidis E,Zeidler C,et
al.Tailoring the Cut-off values of the visual analogue scale
and numeric rating scale in itch assessment.Acta Derm
Venereol.2017;97:759–760.doi:10.2340/00015555-2642.
[20]Oexle N,Rüsch N.Stigma— risikofaktor und
Konsequenz suizidalen Verhaltens:implikationen für die
Suizidprävention.[Stigma— risk factor and consequence
of suicidal behavior: implications for suicide prevention].
Nervenarzt.2018;89:779–83.10.1007/s00115-017-0450-8.
[21]Stumpf A,Ständer S,Warlich B,et al.Relations
between the characteristics and psychological comorbidities of
chronic pruritus differ between men and women:women are
more anxious than men.Br J Dermatol.2015;172:1323–1328.
doi:10.1111/bjd.13492.
[22]Boozalis E,Tang O,Patel S,et al.Ethnic differences
and comorbidities of 909 prurigo nodularis patients.
J Am Acad Dermatol.2018;79:714–719.e3.doi:10.1016/
j.jaad.2018.04.047.
[23]Yook HJ,Lee JH.Prurigo Nodularis:Pathogenesis and
the Horizon of Potential Therapeutics.Int J Mol Sci.2024 May
9;25(10):5164.doi:10.3390/ijms25105164.PMID:38791201;P
MCID:PMC11121340.
[24]Calugareanu A,Specque F,Demouche S,et
al.Transcriptomic landscape of prurigo nodularis lesional skin
CD3+T cells using single-cell RNA-sequencing.J Invest
Dermatol.2023doi:10.1016/j.jid.2023.05.011.
[25]Bao A,Ma E,Cornman H,Kambala A,et
al.Dupilumab Therapy Modulates Circulating Inflammatory
Mediators in Patients with Prurigo Nodularis.JID Innov.2024
Apr 12;4(4):100281.doi:10.1016/j.xjidi.2024.100281.PMID:3
8947360;PMCID:PMC11214504.
[26]Napolitano M,Fabbrocini G,Scalvenzi M,et
al.Effectiveness of dupilumab for the treatment of generalized
prurigo nodularis phenotype of adult atopic dermatitis.
Dermatiti s.2020;31:81–4
[27]Beck LA,Bissonnette R,Deleuran M,et al.Dupilumab
in Adults With Moderate to Severe Atopic Dermatitis:A
5-Year Open-Label Extension Study.JAMA Dermatol. 2024
Jul 10:e241536.doi:10.1001/jamadermatol.2024.1536.Epub
ahead of print.PMID: 38985486;PMCID:PMC11238067.
Refbacks
- 当前没有refback。
